Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
132.3 USD | -1.03% | -3.24% | +0.36% |
Financials (USD)
Sales 2024 * | 2.22B | Sales 2025 * | 2.55B | Capitalization | 13.45B |
---|---|---|---|---|---|
Net income 2024 * | 431M | Net income 2025 * | 675M | EV / Sales 2024 * | 5.16 x |
Net cash position 2024 * | 2B | Net cash position 2025 * | 2.81B | EV / Sales 2025 * | 4.17 x |
P/E ratio 2024 * |
32.9
x | P/E ratio 2025 * |
21.1
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +0.28% | ||
1 week | -0.69% | ||
Current month | -1.27% | ||
1 month | -4.99% | ||
3 months | +0.01% | ||
6 months | +12.78% | ||
Current year | +1.46% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 254 M€ | +13.39% | - | |
3.81% | 1 M€ | -1.33% | - | |
1.85% | 8 M€ | -.--% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 131.9 | -1.32% | 648 889 |
24-06-05 | 133.7 | +0.16% | 779,166 |
24-06-04 | 133.5 | -4.60% | 1,281,189 |
24-06-03 | 139.9 | +3.33% | 862,001 |
24-05-31 | 135.4 | -0.91% | 1,537,370 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.46% | 13.45B | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.95% | 22.67B | |
-9.65% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+24.22% | 11.32B | |
+86.61% | 9.32B |
- Stock Market
- Equities
- NBIX Stock